Zolgensma (onasemnogene abeparvovec-xioi) Letter of Medical Necessity
Zolgensma (onasemnogene abeparvovec-xioi) is the highest-priced one-time therapy in U.S. healthcare (~$2.1M) and prior authorization requirements are uniformly strict. A Letter of Medical Necessity must establish genetic confirmation, age eligibility, AAV9 antibody status, and a designated administration center.
FDA-Approved Indications
- ● spinal muscular atrophy (SMA) in pediatric patients <2 years of age with bi-allelic mutations in the SMN1 gene
Why Zolgensma Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Bi-allelic SMN1 mutation not confirmed by genetic testing
- 2. Anti-AAV9 antibody titer not documented (must be ≤1:50)
- 3. Patient age >2 years at time of infusion
- 4. Permanent ventilation or tracheostomy excluding eligibility
- 5. Center-of-excellence administration site not designated
- 6. Outcomes-based contracting documentation incomplete
What to Include in a Zolgensma Letter of Medical Necessity
Document genetic confirmation of bi-allelic SMN1 mutations and SMN2 copy number, SMA type and motor function baseline (CHOP-INTEND, HFMSE), age at planned infusion (must be <2 years), anti-AAV9 antibody titer ≤1:50, swallowing and respiratory baseline, immunosuppression plan (prednisolone), liver function, troponin baseline, and treatment plan at a designated infusion center.
Key clinical evidence to cite:
- ✓ STR1VE-US, STR1VE-EU, STR1VE-AP trials — survival without permanent ventilation
- ✓ SPR1NT presymptomatic trial — motor milestones in newborns identified by NBS
- ✓ START Phase 1 long-term follow-up (>5 years)
Relevant guidelines:
- 📖 Cure SMA Treatment Algorithm
- 📖 AAN SMA Standard of Care Consensus Statement
Zolgensma Prior Authorization Criteria
Standard criteria across major US payers for Zolgensma. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Zolgensma
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Zolgensma Prior Authorization FAQ
Why was my Zolgensma prior authorization denied?
The most common denial reasons for Zolgensma are: Bi-allelic SMN1 mutation not confirmed by genetic testing; Anti-AAV9 antibody titer not documented (must be ≤1:50); Patient age >2 years at time of infusion; Permanent ventilation or tracheostomy excluding eligibility; Center-of-excellence administration site not designated; Outcomes-based contracting documentation incomplete.
What should a Zolgensma Letter of Medical Necessity include?
Document genetic confirmation of bi-allelic SMN1 mutations and SMN2 copy number, SMA type and motor function baseline (CHOP-INTEND, HFMSE), age at planned infusion (must be <2 years), anti-AAV9 antibody titer ≤1:50, swallowing and respiratory baseline, immunosuppression plan (prednisolone), liver function, troponin baseline, and treatment plan at a designated infusion center.
Which payers cover Zolgensma?
Zolgensma is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare, State Medicaid, though formulary tier and prior authorization criteria vary.